Valeant Again Boosts Skin Care Biz With $500M PreCision Buy
Under the transaction's terms, Quebec-based Valeant will pony up $475 million in cash, plus another $25 million if PreCision hits unspecified sales milestones. The deal adds to a string of pickups aimed at bringing Valeant into the top five drug companies, based on market capitalization, by 2015.
The company has said...
To view the full article, register now.